⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 9, 2024PLoS ONEOpen Access

Sequential interleukin-17 inhibitors for moderate-to-severe plaque psoriasis who have an IL-17 inhibitors failure in a resource limited country: An economic evaluation

Piyameth Dilokthornsakul Ratree Sawangjit Nopadon Noppakun Natta Rajatanavin Bensachee Pattamadilok Leena Chularojanamontri Unchalee Permsuwan

View Full Paper

Ask AI

Bookmark

Share

Abstract

Biologics has been known to be effective for patients with psoriasis. However, optimal treatment pathways and their cost-effectiveness are limited in a resource-limited country. This study assessed the cost-effectiveness of different sequential biologics for moderate-to-severe plaque psoriasis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dilokthornsakul et al. (2024) studied this question.

synapsesocial.com/papers/68e5ceabb6db64358756494e https://doi.org/10.1371/journal.pone.0307050

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety of Il-17 Inhibitors in Moderate-To-Severe Plaque Psoriasis: A Systematic Review and Meta-AnalysisMeta-Analysis · 2026
2Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis)Retrospective Study · 2024 · 55 citations
3Comparative Efficacy of Interleukin Inhibitors and JAK Inhibitors in Moderate to Severe Plaque PsoriasisLiterature Review · 2026
4Comparative Analysis of the Long-Term Real-World Efficacy of Interleukin-17 Inhibitors in a Cohort of Patients with Moderate-to-Severe Psoriasis Treated in Poland2025 · 4 citations
5High-Dose, Extended Half-Life IL-23 Inhibitors: the Next Big Step in Psoriasis Care?Early-Phase Clinical Trial · 2026 · 1 citations

More related papers

Age affects drug survival rates of interleukin (<scp>IL</scp>)‐17 and <scp>IL</scp>‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study2024
Systemic Pharmacological Treatments for Chronic Plaque Psoriasis2026
A comparison of anti-IL-17A, anti-TNF, and anti-IL-12/23 biologics for moderate-to-severe plaque psoriasis in India, based on cost per NNT and its effect on the therapeutic landscape and outcome2025

More from PLoS ONE

Facial feature prioritization by forensic specialistsWed,
Comparison of facial muscle activity between younger and older Japanese adults: A cross-sectional studyWed,